Fortschritte der Medizin · 1992
[Therapy with H2 receptor antagonists in childhood. Use of ranitidine in duodenal and gastric ulcer and reflux esophagitis].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bender S W
Аннотация
AIMS: Representation of common characteristics and peculiarities of the treatment with H2-receptor antagonists of duodenal and gastric ulcer and gastro-esophageal reflux in childhood in comparison with adults, taking ranitidine as an example.
MAJOR POINTS: In the treatment of primary and chronic duodenal and gastric ulcers, ranitidine at doses of up to 10 mg/kg/day, given in two fractions (up to 300 mg daily) is a proven form of therapy. The endoscopically confirmed healing rates after 6 to 8 weeks of acute treatment vary between 80 and 100%. The recurrence rate in children with duodenal ulcer is high, so that long-term treatment with 4 to 5 mg/kg/day (evening dose) is added. Following a recurrent ulcer, treatment should be continued for one to two years. Ranitidine has been used with success for the treatment of gastroesophageal reflux. Shorter intervals between administrations (3 times a day) with a total dose of up to 10 mg/kg/day are to be recommended. More experience is required in this area. At therapeutic doses, ranitidine shows hardly any side effects in children, even with long-term treatment, and can be considered to be very well tolerated by this age group, including babies.
MAJOR POINTS: In the treatment of primary and chronic duodenal and gastric ulcers, ranitidine at doses of up to 10 mg/kg/day, given in two fractions (up to 300 mg daily) is a proven form of therapy. The endoscopically confirmed healing rates after 6 to 8 weeks of acute treatment vary between 80 and 100%. The recurrence rate in children with duodenal ulcer is high, so that long-term treatment with 4 to 5 mg/kg/day (evening dose) is added. Following a recurrent ulcer, treatment should be continued for one to two years. Ranitidine has been used with success for the treatment of gastroesophageal reflux. Shorter intervals between administrations (3 times a day) with a total dose of up to 10 mg/kg/day are to be recommended. More experience is required in this area. At therapeutic doses, ranitidine shows hardly any side effects in children, even with long-term treatment, and can be considered to be very well tolerated by this age group, including babies.